About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The search for quality and innovation has always been an inherent part of the activity of the Stroke Research Group and represents the common thread that leads us to excellence and continuous improvement.
In recent years, the Stroke Research Group has established itself as a leader in the management, recruitment and international coordination of multicenter clinical trials, as well as in the development of patents for new thrombectomy devices and the creation of new technological solutions and digital platforms to improve the diagnosis, treatment and follow-up of stroke patients. Robust strategic alliances have also been consolidated with public and private entities that ensure the viability and scalability of the research projects initiated in our group.
The Stroke Research Group is made up of a transversal and multidisciplinary team that shares a common idea: to contribute from its area of knowledge to the care and management of stroke through the effective transfer of knowledge and the complementarity of the processes of clinical research.
IP: Marta Aurora Rubiera Del Fueyo Collaborators: Estefania Montiel, Marc Rodrigo Gisbert Funding agency: Instituto de Salud Carlos III Funding: 90750 Reference: PI20/01768 Duration: 01/01/2021 - 30/06/2025
IP: David Rodriguez Luna Collaborators: Noelia Rodríguez Villatoro, Olalla Pancorbo Rosal Funding agency: Instituto de Salud Carlos III Funding: 38720 Reference: PI20/00834 Duration: 01/01/2021 - 30/06/2025
IP: Marta Olive Gadea Collaborators: Marc Ribó Jacobi Funding agency: Instituto de Salud Carlos III Funding: 107690 Reference: PI21/01967 Duration: 01/01/2022 - 31/12/2024
IP: Marta Aurora Rubiera Del Fueyo Collaborators: Maria Victoria Sala Sanz de Madrid, Cristina Guirao Martinez, Claudia Meza Burgos, Federica Rizzo, Ester Sanchez Gavilan, David Rodriguez Luna Funding agency: EUROPEAN COMMISSION Funding: 567950 Reference: VALIDATE_HE-HLTH-DISEASE21 Duration: 01/05/2022 - 30/04/2026
PMID: 37919456 Journal: BONE MARROW TRANSPLANTATION Year: 2023 Reference: Bone Marrow Transplant. 2023 Nov 2. doi: 10.1038/s41409-023-02114-0. Impact factor: Publication type: Paper in international publication Authors: Albert, Eliseo; Amat, Paula; Balaguer, Aitana; Barba, Pere; Beas, Francisco; Benzaquen, Ana; Bhuva, Parita; Bonafe, Alain; Budzik, Ronald F; Campos, Diana et al. DOI: 10.1038/s41409-023-02114-0
PMID: 37919201 Journal: Enfermedades infecciosas y microbiologia clinica ( Year: 2023 Reference: Enferm Infecc Microbiol Clin (Engl Ed). 2023 Oct 31:S2529-993X(23)00255-1. doi: 10.1016/j.eimce.2023.07.007. Impact factor: Publication type: Clinical guide Authors: Albucher, Jean Francois; Ariza, Javier; Baeza, Jose; Belzunegui-Otano, Joaquin; Benito, Natividad; Buetikofer, Lukas; Cobo, Javier; Del-Toro, Maria-Dolores; Dobrocky, Tomas; Eker, Omer et al. DOI: 10.1016/j.eimce.2023.07.007
PMID: 37932449 Journal: Clinical Neuroradiology Year: 2023 Reference: Clin Neuroradiol. 2023 Nov 6. doi: 10.1007/s00062-023-01354-3. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Almenar-Bonet, Luis; Andersson, Tommy; Atienza, Felipe; Aurelio Sarralde-Aguayo, Jose; Baguda, Javier De Juan; Barge-Caballero, Eduardo; Blasco-Peiro, Teresa; Camino, Manuela; Carlos Sanchez-Salado, Jose; Coll, Elisabeth et al. DOI: 10.1007/s00062-023-01354-3
PMID: 37935260 Journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Year: 2023 Reference: J Allergy Clin Immunol. 2023 Nov 5:S0091-6749(23)01390-8. doi: 10.1016/j.jaci.2023.10.018. Impact factor: Publication type: Paper in international publication Authors: Albert, Michael H; Andersson, Tommy; Aumann, Volker; Bakhtiar, Shahrzad; Barlogis, Vincent; Booth, Claire; Buddingh, Emmeline P; Cagdas, Deniz; Castelle, Martin; Chan, Alice Y et al. DOI: 10.1016/j.jaci.2023.10.018
UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.
The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.
Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.
